GLP-1 Prices in 2027: Confirmed List Prices and Medicare Changes
As of October 21, 2026, confirmed GLP-1 prices for 2027 include two distinct measures—not one amount every patient will pay. Novo Nordisk announced monthly U.S. list prices, described as wholesale acquisition cost (WAC) in its announcement, of $675 for specified Wegovy, Ozempic and Rybelsus presentations, effective January 1, 2027. Separately, CMS reports a $274 single maximum fair price (MFP) per 30-day-equivalent supply for the Ozempic; Rybelsus; Wegovy selected-drug group, effective the same date.
The announced monthly list price and Medicare MFP per 30-day-equivalent supply are different measures with different scopes and should not be treated as interchangeable. Neither amount is a universal copay or a promise of 2027 retail prices. Understanding what each figure represents is essential when interpreting drug-pricing data.
Table of contents
- Confirmed GLP-1 price changes for 2027
- What the announced 2027 prices cover
- What CMS’s $274 Medicare measure represents
- List price, cash price, acquisition measure and out-of-pocket cost
- How to read the confirmed figures
- Method and limitations
- Frequently asked questions
- Explore the QOPE Drug Pricing dataset
- Sources
Confirmed GLP-1 price changes for 2027
These announced changes take effect on January 1, 2027. The manufacturer list prices and Medicare negotiated price use different measures; neither establishes a universal patient copay. The manufacturer names the presentations shown and also states that the action applies to all doses of these medicines; the table is not a claim that other doses are excluded.
| Product or selected-drug group | Price measure | Announced amount | Effective date |
|---|---|---|---|
| Wegovy injection 2.4 mg and tablets 25 mg | Manufacturer-announced monthly U.S. list price/WAC | $675 | January 1, 2027 |
| Ozempic injection 0.5 mg, 1 mg and 2 mg | Manufacturer-announced monthly U.S. list price/WAC | $675 | January 1, 2027 |
| Rybelsus tablets 7 mg or 14 mg | Manufacturer-announced monthly U.S. list price/WAC | $675 | January 1, 2027 |
| Ozempic; Rybelsus; Wegovy selected-drug group | CMS single maximum fair price per 30-day-equivalent supply | $274 | January 1, 2027 |
What the announced 2027 prices cover
Novo Nordisk’s announcement names three products and specific presentations for a $675 monthly U.S. list price, effective January 1, 2027; it does not announce a price for every product in the GLP-1 class.
- Wegovy injection 2.4 mg and tablets 25 mg
- Ozempic injection 0.5 mg, 1 mg and 2 mg
- Rybelsus tablets 7 mg or 14 mg
The company describes these amounts as list prices, or WAC. It also says that its list-price changes do not affect direct-to-patient self-pay prices. That statement addresses the effect of the list-price changes; it does not establish a new self-pay price or support projecting how self-pay prices may change.
The announcement does not establish a 2027 price for Mounjaro or Zepbound. The change for the specified Novo Nordisk presentations should not be treated as a class-wide price change.
What CMS’s $274 Medicare measure represents
CMS's September 21, 2026 file reports an initial price applicability year (IPAY) 2027 single MFP of $274 per 30-day-equivalent supply for the Ozempic; Rybelsus; Wegovy selected-drug group, effective January 1, 2027. CMS identifies these products among the Medicare Part D drugs selected for its second negotiation cycle. This program price does not establish an individual's coverage, eligibility or copay.
The single MFP differs from the NDC-specific pricing fields in the same file. It should not be treated as a uniform price for every NDC package or substituted for a patient's bill. The recorded effective date is in 2027; the figure is not an observed 2027 transaction as of October 21, 2026.
List price, cash price, acquisition measure and out-of-pocket cost
“Price” can refer to different measures in drug purchasing and payment. Keeping the terms distinct helps prevent misleading comparisons.
List price/WAC is the manufacturer-announced amount in this case: $675 per month for the specified presentations beginning in 2027. It is not, by itself, a patient bill or a guaranteed retail transaction price.
NADAC, or National Average Drug Acquisition Cost, is a pharmacy acquisition-cost reference. Medicaid describes it as averaging survey invoice prices from retail community pharmacies. An acquisition-cost reference is a different measure from the manufacturer-announced list prices and the specific CMS MFP entry reported here.
Direct-to-patient self-pay prices are another distinct category. Novo Nordisk says its announced list-price changes do not affect direct-to-patient self-pay prices. That statement does not supply a self-pay amount or make the list price a basis for inferring one.
Patient out-of-pocket amounts are distinct as well. The confirmed figures do not specify a universal copay or what a particular patient will owe. The $274 MFP should not be presented as a guaranteed patient cost.
How to read the confirmed figures
As a practical comparison method, we recommend checking the measure, scope and unit before interpreting amounts. The monthly manufacturer list price and Medicare MFP per 30-day-equivalent supply are different measures and should not be treated as interchangeable. An analytical comparison must state each measure's program scope, units and methodology. CMS’s NDC-specific values offer different pricing detail from the single group-level figure and use different units. Keep those scopes and units visible rather than presenting the amounts as equivalent.
For a dated acquisition-cost comparison, we recommend retaining the NDC, pricing unit and effective date alongside each reported per-unit value. This keeps the comparison tied to its product, unit and observation date rather than treating every quoted drug price as the same measure.
Method and limitations
This comparison uses Novo Nordisk’s February 24, 2026 announcement and the CMS selected-drug negotiated-price file released September 21, 2026. The CMS records were filtered for initial price applicability year 2027, semaglutide, an effective date of January 1, 2027, and no MFP end date. The resulting report retained 38 NDC rows, each reporting $274 for the single MFP per 30-day-equivalent supply.
The archived CMS snapshot is CMS_Negotiation_Program_Selected_Drug_List_and_Maximum_Fair_Price_Data_File_20260921.csv, retrieved October 21, 2026. Its CSV SHA-256 is 2cb50b9ed03b1362cdd4a9623d51a5b1bea73e204bf463412ee9ac0392ae2455. The filename identifies the release used for this comparison; later CMS updates may contain different records.
The comparison reports the values and scope stated in those sources. It does not estimate rebates, predict retail transactions, calculate patient costs or establish prices for products not covered by the announcements. In particular, it does not establish a 2027 price for Mounjaro or Zepbound.
For related analyses of prescription patterns—not price measures—see GLP-1 drug rankings and GLP-1 prescriptions by state. These Medicaid prescription rankings address different questions from list-price, MFP or acquisition-cost data.
Frequently asked questions
These answers distinguish the announced list price from CMS’s MFP measure and clarify what neither figure says about patient costs.
Is $675 the 2027 price every patient will pay?
No. It is the announced monthly U.S. list price/WAC for the specified Wegovy, Ozempic and Rybelsus presentations. It is not a universal copay or guaranteed retail price. Novo Nordisk says the announced list-price changes do not affect its direct-to-patient self-pay prices.
Does the CMS $274 MFP mean a $274 copay?
No. The $274 is the Medicare Drug Price Negotiation Program single MFP per 30-day-equivalent supply for the Ozempic; Rybelsus; Wegovy selected-drug group. It is neither a uniform NDC-specific unit or package price nor a guaranteed patient out-of-pocket amount.
Are these prices already observed in 2027?
No. As of October 21, 2026, they are announced prices scheduled to take effect January 1, 2027—not observed 2027 transactions.
When interpreting these figures, keep each measure’s scope and unit attached to the amount. Neither one, by itself, tells a patient’s final cost.
Explore the QOPE Drug Pricing dataset
Open the QOPE Drug Pricing dataset, enter Ozempic in Search drug pricing, and press Enter. For a matching record, read the NDC and description alongside NADAC per unit, pricing unit, effective date and as-of date. Use the dates and units to identify which product observation you are comparing.
This lookup returns acquisition-cost reference records. The manufacturer list prices and CMS MFP figures in this article come from the official sources below; a QOPE search does not turn a historical NADAC observation into a confirmed 2027 price.